Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
A reverse split and transfer to the Nasdaq Capital Market preceded the resolution of the bid-price deficiency.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liminatus Pharma (LIMN) regained compliance with Nasdaq's minimum bid price rule, closing the review of its share price.
Nasdaq notified the company on January 15, 2026, that its closing bid price had remained below $1.00 for 30 consecutive business days. Following an appeal and hearing, the Nasdaq Hearings Panel transferred Liminatus to the Nasdaq Capital Market effective August 4 and gave it until September 3 to demonstrate compliance with that market's bid price rule. Liminatus effected a 1-for-50 reverse stock split at the close of trading on August 20. Nasdaq's September 24 notice stated that the closing bid price exceeded $1.00 for 13 consecutive trading days from August 21 through September 9; the matter is closed.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointBid-price compliance restored after 13 consecutive trading days above $1.00 per share; Nasdaq closed the matter.
Negative
- Moderate pointNasdaq Capital Market transfer took effect August 4 after the company appealed its bid-price deficiency.
- Moderate point1-for-50 reverse stock split took effect at the close of trading on August 20.
- Minor pointClosing bid price had remained below $1.00 for 30 consecutive business days before Nasdaq's January 15 notice.
Key Figures
- Prior bid-price deficiency
- Below $1.00 for 30 consecutive business days
- Nasdaq notice received January 15, 2026
- Compliance extension deadline
- September 3, 2026
- Deadline to demonstrate minimum-bid compliance
- Reverse stock split
- 1-for-50
- Effective at the close of trading on August 20, 2026
- Closing bid price
- Above $1.00 per share
- Nasdaq compliance evidence
- Compliance period
- 13 consecutive trading days
- August 21 to September 9, 2026
Historical Context
-
Nasdaq transferred listing and extended the minimum-bid compliance deadline through September 3.
-
Company announced a reverse split ahead of its minimum-bid compliance demonstration.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
reverse stock split financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
FULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq’s minimum bid price rule.
As previously disclosed, on January 15, 2026 the Company received a notice from Nasdaq indicating that the closing bid price of the Company’s common stock had been below
Following an appeal and hearing before the Nasdaq Hearings Panel, the Panel determined to transfer the Company to The Nasdaq Capital Market effective August 4, 2026 and granted the Company an extension to demonstrate compliance with Nasdaq Listing Rule 5550(a)(2) (the applicable minimum bid price requirement for The Nasdaq Capital Market) (the “Bid Price Rule”) by September 3, 2026.
At the close of trading on August 20, 2026, the Company effected a 1-for-50 reverse stock split.
On September 24, 2026, the Company received a notice from Nasdaq stating that, for the 13 consecutive trading days from August 21, 2026 to September 9, 2026, the closing bid price of the Company’s common stock had been above
About Liminatus
Liminatus Pharma, Inc. (Nasdaq: LIMN) is a biotechnology company developing innovative immuno-oncology and cell therapy candidates. The Company’s portfolio includes IBA101, a next-generation anti-CD47 monoclonal antibody, as well as oncology-focused cellular therapy programs including IBC101, a CD19xCD22 bivalent CAR-T candidate for B-cell malignancies. Liminatus is focused on advancing differentiated therapeutic approaches designed to address unmet needs in cancer treatment.
Forward-Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the applicable federal securities laws. All statements that are not statements of historical fact are forward-looking statements. Forward-looking statements may be identified by the use of words such as “may,” “could,” “would,” “should,” “predict,” “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” or other similar expressions that predict or indicate future events or that are not statements of historical matter. These statements are based on assumptions and on the current expectations of the Company’s management and are not predictions of actual performance. Many actual events and circumstances are beyond the control of Liminatus. These forward-looking statements are subject to a number of risks and uncertainties, including: (i) changes in business, market, financial, political and legal conditions; (ii) the Company’s continued ability to implement business plans; (iii) the risk of downturns, new entrants and a changing regulatory landscape in a highly competitive industry in which the Company operates; (iv) the Company’s continued listing on Nasdaq; and (v) those risks and uncertainties discussed in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which that are beyond the Company’s control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results. The forward-looking statements contained in this press release speak only as of the date of this press release and the Company undertakes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this press release, unless required by law.
For more information, please contact:
Liminatus Pharma, Inc.
Chris Kim, CEO
info@liminatuspharma.com
(213) 273-5453
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.